Cipla gets WHO nod to sell TB preventing drug in HIV patients
New Delhi: Drug major Cipla on Thursday said it has received approval from the World Health Organisation (WHO) for Q-TIB, a combination drug indicated to help prevent tuberculosis infection in people living with HIV.
Q-TIB is a novel fixed dose combination in a single tablet and it is for the first time that such a combination has been made available in the world. The company will market the product globally, Cipla said in a statement.
Q-TIB will help prevent tuberculosis infection in people living with HIV as they face a challenged immune system and are prone to infections, which constitute the major source of premature deaths among them.
As per WHO’s Global TB Report, 2016, about one million people died of AIDS-related illness. Most of them succumbed to infections, and among them, 4 lakh died of tuberculosis.
Cipla shares were trading 1.31% down at Rs600.55 apiece on BSE on Thursday.
- Hyundai to hike vehicle prices by up to 2% from June, no change in new Creta prices
- US eyes India’s dairy market, seeks to pull sops to textiles industry
- Oil prices firm with Brent nearing $80 on supply worries
- ONGC, OIL face risk of subsidy sharing: Moody’s
- Intel finds another chip exploit, says fix already in place